Latest news
Database of Publicly Announced U.S. FDA RMAT Designations, 2026 - BioInformantBioInformant · Sat, 08 Aug 2026 07:00:00 GMTAddressing Manufacturing and Access Barriers in Advanced Therapeutics - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 19:52:06 GMTLexeo Therapeutics Receives FDA Regenerative Medicine - GlobeNewswireGlobeNewswire · Wed, 05 Aug 2026 11:00:00 GMTLexeo's heart gene therapy gets FDA status after interim data - Stock TitanStock Titan · Wed, 05 Aug 2026 11:00:00 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 11:00:00 GMTAllogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMTAllogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT